509.15
+1.48%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Unichem Laboratories
Its shares trade on NSE under the ticker UNICHEMLAB.NS. It has been listed since 10 January 1995. In the fiscal year to 31 March 2025, it reported revenue of ₹21.11bn and net income of ₹1.38bn. At that date it held total assets of ₹35.69bn and shareholders' equity of ₹24.51bn.
Unichem Laboratories Ltd. is a pharmaceutical company, which engages in the manufacturing and marketing of pharmaceutical formulations. The company is headquartered in Mumbai, Maharashtra. The firm is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. The company manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. The company has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The firm is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Jan 1995
- Employees
- 3,123
- Website
- unichemlabs.com ↗
Leadership
Pay as last reported
- Dr. Prakash ModyNon-Executive Non-Independent Chairman of the Board, since 2023₹55.5m
- Mr. Sandip GhumeDeputy Chief Financial Officer and Institutional Investors, Financial Analysts
- Mr. Pradeep BhandariChief Compliance Officer, Company Secretary
- Mr. Pabitrakumar BhattacharyyaManaging Director, Additional Director, since 2023
- Mr. Pranay GodhaAdditional Non-Executive Non-Independent Director
- Mr. Anand KusreNon-Executive Independent Director
- Dr. B. Kinnera MurthyNon-Executive Independent Director₹1.2m
- Mrs. Priti PuriNon-Executive Independent Director
- Mr. Arun TodarwalNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Mumbai with 3,123 employees
- Focus on product development and manufacturing complex APIs and dosage forms
- Manufactures and markets branded generics and generics globally
Weaknesses
- No specific weaknesses mentioned in the provided information
- No details on financial performance or market share
- No mention of R&D investment or innovation metrics
Opportunities
- Expansion into new therapeutic areas like gastroenterology and cardiology
- Growth in contract manufacturing for novel drug delivery systems
- International expansion through subsidiaries in USA, Brazil, and UK
Threats
- No specific threats mentioned in the provided information
- No details on regulatory challenges or competition
- No mention of market saturation or economic risks
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.